scholarly article | Q13442814 |
P50 | author | Georgina L. Hold | Q61912899 |
Christopher Sj Probert | Q90014617 | ||
Ashley Bond | Q90073845 | ||
Stephen Lewis | Q92091595 | ||
Bernard M. Corfe | Q47189352 | ||
P2093 | author name string | Paul Rooney | |
Sanchoy Sarkar | |||
Paul O'Toole | |||
Rosemary Greenwood | |||
Michael Burkitt | |||
P2860 | cites work | Effects of Curative Colorectal Cancer Surgery on Exhaled Volatile Organic Compounds and Potential Implications in Clinical Follow-up. | Q51572808 |
A bacterial driver–passenger model for colorectal cancer: beyond the usual suspects | Q57709818 | ||
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population | Q81191664 | ||
Exhaled volatile organic compounds identify patients with colorectal cancer | Q85613483 | ||
Adenoma detection rate and risk of colorectal cancer and death | Q88151880 | ||
The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production in vivo in healthy subjects: a pilot trial comparison to concurrent breath analysis | Q90686294 | ||
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma | Q24603069 | ||
Review article: next generation diagnostic modalities in gastroenterology--gas phase volatile compound biomarker detection | Q26995194 | ||
Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests | Q28079672 | ||
Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice | Q28303049 | ||
Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis | Q28543425 | ||
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. | Q33865884 | ||
Metab: an R package for high-throughput analysis of metabolomics data generated by GC-MS. | Q33940342 | ||
Dysbiosis signature of fecal microbiota in colorectal cancer patients | Q34754690 | ||
MetaboAnalyst 3.0--making metabolomics more meaningful | Q35610559 | ||
Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal Cancer | Q35667382 | ||
Urinary Volatile Organic Compounds for the Detection of Prostate Cancer | Q35849909 | ||
Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests | Q36221516 | ||
Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review | Q36966177 | ||
The National Health Service Bowel Cancer Screening Program: the early years | Q38125254 | ||
Colorectal cancer prevention in Europe: burden of disease and status of screening programs | Q38188312 | ||
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know | Q38515202 | ||
Ingestible Sensors. | Q38672251 | ||
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing | Q38797269 | ||
Microbial production of propanol. | Q38855177 | ||
Investigation of Volatile Organic Compounds Emitted from Faeces for the Diagnosis of Giardiasis | Q40982367 | ||
An updated Asia Pacific Consensus Recommendations on colorectal cancer screening | Q44457129 | ||
The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis | Q47964151 | ||
Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. | Q50516321 | ||
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing. | Q51315329 | ||
Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. | Q51412952 | ||
P433 | issue | 8 | |
P921 | main subject | feces | Q496 |
biomarker | Q864574 | ||
volatile organic compound | Q910267 | ||
colorectal cancer | Q188874 | ||
colorectal carcinoma | Q25493920 | ||
P304 | page(s) | 1005-1012 | |
P577 | publication date | 2019-03-03 | |
P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
P1476 | title | Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer | |
P478 | volume | 49 |
Q100694605 | A risk-stratified approach to colorectal cancer prevention and diagnosis |
Q89910574 | Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? |
Q90250266 | Digging deeper into volatile organic compounds associated with cancer |
Q90101614 | Intestinal gases: influence on gut disorders and the role of dietary manipulations |
Q92138830 | Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer |
Search more.